Ergun, CansuKiraz, YagmurAyna Duran, Gizem2025-07-252025-07-2520251120-009X1973-9478https://doi.org/10.1080/1120009X.2025.2527464https://hdl.handle.net/20.500.14365/6280Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analyses. Publicly available GEO microarray datasets were analyzed, including data from 615 AML patients and 22 healthy controls. Multivariate Cox regression identified hazardous genes impacting survival. Protein-protein interaction networks using CytoScape revealed hub genes such as CCT5, ZBTB16, APP, and PTPN6. Functional enrichment revealed key AML-related pathways, such as PI3K/Akt and NF-kappaB signaling. Drug repurposing using the LINCS L1000CDS2 database highlighted potential therapeutics, including 16-Hydroxytriptolide and Tryptosthin AG-1478, with roles in reversing hazardous gene expression patterns. Additional candidates such as Vemurafenib, Parthenolide and Wortmannin, demonstrated promise as targeted agents. These findings underscore the potential of integrating bioinformatics and drug discovery to identify precision medicine in AML. Further studies are warranted to validate these targets and explore their clinical utility.eninfo:eu-repo/semantics/closedAccessAcute Myeloid LeukemiaDNA MicroarraysGene Expression ProfilingSurvival AnalysisDrug RepurposingArticle10.1080/1120009X.2025.25274642-s2.0-105010052696